Business Context and Reporting Period
This Form 8-K was filed by OvaScience, Inc. (noted as Tempest Therapeutics, Inc. in request metadata) on December 5, 2012. The report discloses a new employment agreement and compensatory arrangements for Michelle Dipp, M.D., Ph.D., who was appointed as President and Chief Executive Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on executive compensation details.
Material Changes and Compensation Details
On December 5, 2012, the Company entered into a Letter Agreement with Dr. Dipp. The equity grants are structured as follows:
- Restricted Stock Units (Time-Based): 128,205 shares vesting quarterly over two years.
- Restricted Stock Units (Performance-Based): 64,103 shares vesting annually over two years upon meeting specific conditions.
- Stock Options: 339,313 shares vesting quarterly over four years.
These equity awards are granted in lieu of cash compensation. They include a change-in-control provision causing immediate vesting and a gross-up payment for excise taxes related to these grants.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingency noted is the acceleration of vesting and tax gross-up provisions triggered by a change in control of the Company.
Investor Verification Checklist
- Verify the total number of shares authorized for issuance under the new grants (531,621 total units/options).
- Confirm the specific performance conditions required for the 64,103 performance-based RSUs.
- Assess the potential dilution impact of the 339,313 stock options and 192,308 RSUs on existing shareholders.
- Review the Company's cash position to ensure it can fund the excise tax gross-up if a change in control occurs.